A review of the pan-RAS(ON) inhibitor daraxonrasib (RMC-6236) notes a documented reduction in death risk in the Phase 3 RASolute 302 trial but emphasizes that published cardiac-specific endpoint data remain absent at Phase 3 scale. The review describes reproducible vascular findings such as peripheral edema and treatment-emergent hypertension in a minority. The authors frame the safety picture as narrower than mechanistic concerns would suggest, but they caution that limited published myocardial data and a lack of disproportionality signals in early pharmacovigilance do not constitute proof of safety. For cardio-oncology planning, this means real-world monitoring and future trial reporting—troponin, ECG, strain, and ejection fraction endpoints—will be decisive for risk characterization.